Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX79 + HLX01 in glomerulonephritis
NCT07038382Phase 2Recruiting
- Sponsor
- Henlius
- Start
- Aug 2025
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of efgitasialase alfa in membranous nephropathy (MN), lupus nephritis (LN), sponsored by Henlius. Started Aug 2025; status: recruiting.
02
Drugs
efgitasialase alfa
03
Conditions
membranous nephropathy (MN)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07038382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038382.